https://www.fool.com/investing/2021/03/17/why-tonix-pharmaceuticals-stock-is-soaring-today/
Why Tonix Pharmaceuticals Stock Is Soaring Today | The Motley Fool
Mar 17, 2021 - The company reported positive results from a pre-clinical study.
tonix pharmaceuticalsthe motleystocksoaringtoday
https://www.biospace.com/tonix-pharmaceuticals-presents-data-from-retrospective-observational-database-study-on-the-incidence-of-multi-site-pain-symptoms-in-long-covid-patients-at-iasp-2022-world-congress-on-pain
Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the...
Sep 22, 2022 - Tonix Pharmaceuticals Holding Corp. today announced data from a retrospective observational database study in patients diagnosed with Long COVID at the...
tonix pharmaceuticalspresentsdata
https://www.biospace.com/tonix-pharmaceuticals-announces-presentation-at-the-2024-bio-international-convention
Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention - BioSpace
Aug 7, 2024 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline...
bio international conventiontonix pharmaceuticalsannouncespresentation
https://www.finanznachrichten.de/chart-tool/aktie/tonix-pharmaceuticals-holding-corp.htm
TONIX PHARMACEUTICALS Chartanalyse
Chart zur TONIX PHARMACEUTICALS HOLDING CORP Aktie. Alle Charts zu Ihren Aktien.
tonix pharmaceuticalschartanalyse
https://www.biospace.com/tonix-pharmaceuticals-to-present-at-3rd-annual-neuropsychiatric-drug-development-summit
Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit - BioSpace
Nov 9, 2020 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman,...
tonix pharmaceuticals3rd annual
https://www.finanznachrichten.de/nachrichten-2025-05/65382101-tonix-pharmaceuticals-holding-corp-tonix-pharmaceuticals-reports-first-quarter-2025-financial-results-and-operational-highlights-399.htm
Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports First Quarter 2025 Financial...
FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating...
tonix pharmaceuticalsfirst quarterholdingcorpreports
https://www.biospace.com/tonix-pharmaceuticals-announces-poster-presentation-describing-discovery-of-novel-next-generation-oxytocin-analogues-at-the-american-chemistry-society-acs-spring-2024-meeting
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation...
Mar 21, 2024 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development...
tonix pharmaceuticalsposter presentationdiscovery ofannounces
https://www.globenewswire.com/en/news-release/2022/10/31/2544440/28908/en/Tonix-Pharmaceuticals-to-Present-at-the-2022-BioFuture-Conference.html
Tonix Pharmaceuticals to Present at the 2022 BioFuture
CHATHAM, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company,...
tonix pharmaceuticalspresent2022
https://ir.tonixpharma.com/
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat pain, addiction and psychiatric...
tonix pharmaceuticalsholdingcorp
https://www.biospace.com/tonix-pharmaceuticals-to-participate-in-upcoming-november-conferences
Tonix Pharmaceuticals to Participate in Upcoming November Conferences - BioSpace
Nov 11, 2020 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman,...
tonix pharmaceuticalsparticipate inupcomingnovemberconferences
https://www.finanznachrichten.de/aktien-analysen/tonix-pharmaceuticals-holding-corp.htm
TONIX PHARMACEUTICALS-AKTIE kaufen? Analysen, Kursziele & Empfehlungen zu A40VM0
TONIX PHARMACEUTICALS-Aktie jetzt kaufen? Analysen und Kursziele:
tonix pharmaceuticalsaktiekaufenanalysenempfehlungen
https://www.globenewswire.com/news-release/2025/07/10/3113112/28908/en/Tonix-Pharmaceuticals-Announces-Presentation-of-New-Data-on-Mpox-and-Smallpox-Vaccine-Candidate-TNX-801-at-the-Vaccine-Congress-2025.html
Tonix Pharmaceuticals Announces Presentation of New Data on
TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against...
tonix pharmaceuticalsnew dataannouncespresentation
https://menafn.com/1109768256/Tonix-Pharmaceuticals-Announces-Oral-Presentation-On-Mpox-And-Smallpox-Vaccine-Candidate-TNX-801-At-The-Vaccine-Congress-2025
Tonix Pharmaceuticals Announces Oral Presentation On Mpox And Smallpox Vaccine Candidate TNX-801 At...
Tonix Pharmaceuticals Announces Oral Presentation On Mpox And Smallpox Vaccine Candidate TNX-801 At The Vaccine Congress 2025. Single dose vaccination with...
https://www.biospace.com/press-releases/tonix-pharmaceuticals-announces-appointment-of-joseph-hand-esq-as-general-counsel-and-executive-vice-president-of-operations
Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive...
https://www.biospace.com/press-releases/tonix-pharmaceuticals-to-present-at-the-2025-jones-trading-healthcare-and-innovation-conference
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference -...
https://www.biospace.com/press-releases/tonix-pharmaceuticals-announces-first-patient-dosed-in-phase-2-oasis-study-of-tnx-102-sl-for-reduction-of-acute-stress-reaction
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for...
https://www.einpresswire.com/article/399330783/tonix-pharmaceuticals-to-present-additional-phase-2-clinical-results-and-design-of-ongoing-phase-3-trial-in-military-related-ptsd-at-the-2017-military
Tonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3...
Aug 21, 2017 - Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company in Phase 3 development of Tonmya*, or TNX-102 SL, a U.S. Food and Drug
https://www.biospace.com/press-releases/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on-fibromyalgia-at-the-american-academy-of-pain-medicine-aapm-2025-annual-meeting
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia...
https://www.biospace.com/press-releases/tonix-pharmaceuticals-announces-ai-collaboration-with-x-chem-to-develop-broad-spectrum-antivirals
Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals -...
https://www.biospace.com/tonix-pharmaceuticals-announces-agreement-and-initiation-of-enrollment-in-phase-2-trial-with-the-university-of-washington-to-study-tnx-1900-potentiated-intranasal-oxytocin-for-social-anxiety-disorder
Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the...
Jul 17, 2023 - Tonix Pharmaceuticals Holding Corp. , today announced that the first participant has been enrolled in a Phase 2 investigator-initiated, proof-of-concept study...